EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

γ‐Butyrolactone Derivatives of MSA‐2 are STING Prodrugs

Kelton Schleyer iD, Elias A Halabi iD, Ralph Weissleder iD

ChemMedChem · 2024-10 · 19 (19)

DOI: 10.1002/cmdc.202400416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 05.08.2024. Verfasst von Kelton Schleyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA-02114. Hauptthemen laut MEDLINE: Prodrugs, 4-Butyrolactone, Membrane Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CSB Development Fund, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STING agonists are potent enhancers of a pro‐inflammatory response and, thus, potentially useful therapeutics. Unfortunately, many agonists developed to date require complex drug delivery formulations and often have poor water solubility, limiting their use for systemic administration. Here, we report the discovery and chemical characterization of lactones of MSA‐2 as new STING prodrugs with enhanced properties. We show that these prodrugs form efficient inclusion complexes with tumor myeloid cell targeting cyclodextrin nanoparticles and propose a new mechanism of formation and hydrolysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prodrugs4-ButyrolactoneMembrane ProteinsHumansMolecular StructureNanoparticlesCyclodextrinsStructure-Activity RelationshipDose-Response Relationship, DrugLactonesSTING Protein

Stichwörter der Autor:innen

MSA-2STINGcancercyclic dinucleotidelactonesprodrug

Substanzen

Prodrugs4-ButyrolactoneMembrane ProteinsCyclodextrinsLactonesSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA-02114.
  • Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, Boston, MA-02115.

ORCID-Profile: Kelton Schleyer, Elias A Halabi, Ralph Weissleder

Förderung

  • NCI NIH HHS
  • CSB Development Fund
  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Schleyer, K., Halabi, E. A., & Weissleder, R. (2024). γ‐Butyrolactone Derivatives of MSA‐2 are STING Prodrugs. ChemMedChem, 19(19). https://doi.org/10.1002/cmdc.202400416

Vancouver

Schleyer K, Halabi EA, Weissleder R. γ‐Butyrolactone Derivatives of MSA‐2 are STING Prodrugs. ChemMedChem. 2024;19(19). doi:10.1002/cmdc.202400416

BibTeX
@article{Schleyer2024,
  author = {Schleyer, Kelton and Halabi, Elias A and Weissleder, Ralph},
  title = {γ‐Butyrolactone Derivatives of MSA‐2 are STING Prodrugs},
  journal = {ChemMedChem},
  year = {2024},
  volume = {19},
  number = {19},
  doi = {10.1002/cmdc.202400416}
}
Kostenlos starten →